Spark’s Gene Therapy For Hemophilia B Looks To Change Up The Game – Seeking Alpha
Seeking Alpha |
Spark's Gene Therapy For Hemophilia B Looks To Change Up The Game
Seeking Alpha Spark Therapeutics posts positive phase 1/2 results treating patients with Hemophilia B using SPK-9001. Pfizer is expected to lead the rest of the development for the Hemophilia B candidate SPK-9001 by this summer since it is partnered with Spark. |
